Moderna president says there will be ‘chronic’ need for coronavirus booster shots
The booster will help protect from variant strains of the virus
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The president of pharmaceutical company Moderna believes that people will require Covid-19 booster shots in the future to maintain their protection from the coronavirus.
Dr Stephen Hoge, the company's president, told the Associated Press during a Q&A session that he believed a third shot – following the initial two-dose vaccination offered by Moderna – would provide longer-lasting protection.
Dr Hoge called the third shot Moderna's "variant booster”, which aims to extend the effectiveness of the vaccine to protect people from variant strains.
"None of us want to be in a situation next November where we have to go into another lockdown. We've been updating our vaccine to make sure it boosts you back up. That's the variant booster that we're going to have available in the fourth quarter," he said.
According to the doctor, the new variant boosters will take several months to complete.
"With the first version of the vaccine, we did it in about five months, but we had to do the large clinical trials. We won't have to do that now. For a booster targeting variants, we could do it in about three months," he said.
The company is currently testing vaccines and possible booster shots that could be administered to young people.
Thus far, more than 217 million doses of Moderna's vaccine have been distributed in the US.
Last week, the company struck a supply deal with the US for $3.3bn in exchange for another 200 million vaccine doses.
According to the US Department of Defence, Moderna will produce the additional doses at its facility in Cambridge, Massachusetts, with products expected for delivery by the end of March 2022.
It plans to provide the government with another 110 million doses of the vaccine in the year's fourth quarter – alongside the "variant booster" – and another 90 million in the first quarter of 2022.
The majority of vaccinated Americans have either received the Moderna or Pfizer vaccines, and it appears those companies will stay at the forefront of the vaccine effort.
To accommodate this, Moderna is expanding its US-based production facilities in order to create at least 800 million more doses of the vaccine.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments